Loading...

NVAX NOVAVAX INC Company Mergers 8-K Filing

NVVX

NVX

NOVAVAX INC

(NVAX)

2026 8-K

Quarterly Financial Results

License Agreement

Investor Update

Financial Results Report

FDA Approval Update

Lease Assignment Deal

EC Approval Received

Convertible Notes Issued

FDA Approval Update

Debt Exchange Agreement

Investor Meetings

New Product Launches

Financial Statements

Clinical Trials

FDA Application Update

Contract Termination

Investor Update

Quarterly Results

Investor Update

Contract Amendment

Investor Update

Financial Results

Settlement Agreement

FDA Clinical Hold

Market Clarification

Financial Results

Annual Meeting Results

Update for Investors and FD...

Management Changes

Collaboration and License A...

Financial Results

Settlement Agreement with F...

Financial Results

Termination and Settlement ...

Workforce Reduction

Results of Operations and F...

Lawsuit Alleging False Stat...

Appointments, Retirement

Financial Results

Disclosure of Say on Pay Votes

COVID-19 Vaccine Authorization

Financial Results

Settlement Agreement and Se...

Financial Results and Workf...

Amended and Restated By-Laws

Management Change

Banking Relationships

Management Change

Financial Results Announcement

External Links:

Novavax Inc has entered a License Agreement with Pfizer as of January 15, 2026, granting Pfizer non-exclusive rights to its Matrix-M adjuvant technology for up to two infectious diseases. Novavax will receive an upfront payment of $30 million and potential milestone payments totaling up to $500 million, along with royalties from sales.

AI Assistant

NOVAVAX INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.